aspartic acid has been researched along with Lung Neoplasms in 46 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 7.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 3.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (32.61) | 18.7374 |
| 1990's | 5 (10.87) | 18.2507 |
| 2000's | 9 (19.57) | 29.6817 |
| 2010's | 14 (30.43) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, YY | 1 |
| Huang, X | 1 |
| Luo, ZC | 1 |
| Qi, MY | 1 |
| Shan, JJ | 1 |
| Zhang, W | 1 |
| DI, LQ | 1 |
| Nishikawa, G | 1 |
| Kawada, K | 1 |
| Hanada, K | 1 |
| Maekawa, H | 1 |
| Itatani, Y | 1 |
| Miyoshi, H | 1 |
| Taketo, MM | 1 |
| Obama, K | 1 |
| Naz, S | 1 |
| Leiker, AJ | 1 |
| Choudhuri, R | 1 |
| Preston, O | 1 |
| Sowers, AL | 1 |
| Gohain, S | 1 |
| Gamson, J | 1 |
| Mathias, A | 1 |
| Van Waes, C | 1 |
| Cook, JA | 1 |
| Mitchell, JB | 1 |
| Bertero, T | 1 |
| Oldham, WM | 1 |
| Grasset, EM | 1 |
| Bourget, I | 1 |
| Boulter, E | 1 |
| Pisano, S | 1 |
| Hofman, P | 1 |
| Bellvert, F | 1 |
| Meneguzzi, G | 1 |
| Bulavin, DV | 1 |
| Estrach, S | 1 |
| Feral, CC | 1 |
| Chan, SY | 1 |
| Bozec, A | 1 |
| Gaggioli, C | 1 |
| Bouras, N | 1 |
| Bousahba, A | 1 |
| Megaïz, A | 1 |
| de Fraipont, F | 1 |
| Sahraoui, T | 1 |
| Kebir, FZE | 1 |
| Zhou, Y | 1 |
| Lu, LN | 1 |
| Xin, X | 1 |
| Huo, DF | 1 |
| Wu, HB | 1 |
| Qiu, MF | 1 |
| Tan, X | 1 |
| Wang, Y | 1 |
| Shi, L | 1 |
| Xian, L | 1 |
| Guo, J | 1 |
| Liang, G | 2 |
| Chen, M | 1 |
| Yamamoto, H | 1 |
| Higasa, K | 1 |
| Sakaguchi, M | 1 |
| Shien, K | 1 |
| Soh, J | 1 |
| Ichimura, K | 1 |
| Furukawa, M | 1 |
| Hashida, S | 1 |
| Tsukuda, K | 1 |
| Takigawa, N | 1 |
| Matsuo, K | 2 |
| Kiura, K | 1 |
| Miyoshi, S | 1 |
| Matsuda, F | 1 |
| Toyooka, S | 1 |
| Wang, J | 2 |
| Yin, H | 1 |
| Panandikar, A | 1 |
| Gandhi, V | 1 |
| Sen, S | 1 |
| Luo, Y | 1 |
| Wang, X | 3 |
| Du, D | 1 |
| Lin, Y | 1 |
| Lou, TF | 1 |
| Sethuraman, D | 1 |
| Dospoy, P | 1 |
| Srivastva, P | 1 |
| Kim, HS | 1 |
| Kim, J | 1 |
| Ma, X | 1 |
| Chen, PH | 1 |
| Huffman, KE | 1 |
| Frink, RE | 1 |
| Larsen, JE | 2 |
| Lewis, C | 1 |
| Um, SW | 1 |
| Kim, DH | 1 |
| Ahn, JM | 1 |
| DeBerardinis, RJ | 1 |
| White, MA | 1 |
| Minna, JD | 2 |
| Yoo, H | 1 |
| Kang, JH | 2 |
| Lee, SH | 2 |
| Lee, JS | 2 |
| Nam, B | 1 |
| Seong, TW | 1 |
| Son, J | 2 |
| Jang, H | 1 |
| Hong, KM | 2 |
| Lee, C | 1 |
| Kim, SY | 2 |
| Klein, BJ | 1 |
| Cui, G | 1 |
| Yuan, C | 1 |
| Botuyan, MV | 1 |
| Lin, K | 1 |
| Lu, Y | 1 |
| Zhao, Y | 1 |
| Bruns, CJ | 1 |
| Mer, G | 1 |
| Shi, X | 1 |
| Kutateladze, TG | 1 |
| Hong, D | 1 |
| Song, J | 1 |
| Luo, Q | 1 |
| Yang, B | 1 |
| Tao, W | 1 |
| Li, J | 1 |
| Kou, L | 1 |
| Lian, H | 1 |
| Che, X | 1 |
| He, Z | 1 |
| Sun, J | 1 |
| Degrassi, A | 1 |
| Russo, M | 1 |
| Nanni, C | 1 |
| Patton, V | 1 |
| Alzani, R | 1 |
| Giusti, AM | 1 |
| Fanti, S | 1 |
| Ciomei, M | 1 |
| Pesenti, E | 1 |
| Texido, G | 1 |
| Ihle, NT | 1 |
| Byers, LA | 1 |
| Kim, ES | 1 |
| Saintigny, P | 1 |
| Lee, JJ | 1 |
| Blumenschein, GR | 1 |
| Tsao, A | 1 |
| Liu, S | 1 |
| Diao, L | 1 |
| Coombes, KR | 1 |
| Chen, L | 1 |
| Zhang, S | 1 |
| Abdelmelek, MF | 1 |
| Tang, X | 1 |
| Papadimitrakopoulou, V | 1 |
| Lippman, SM | 1 |
| Hong, WK | 1 |
| Herbst, RS | 1 |
| Wistuba, II | 1 |
| Heymach, JV | 1 |
| Powis, G | 1 |
| Li, F | 1 |
| Yu, G | 1 |
| Li, S | 1 |
| Peng, S | 1 |
| Fu, J | 1 |
| Wu, D | 1 |
| Xing, DY | 1 |
| Qi, J | 1 |
| Tan, W | 1 |
| Miao, XP | 1 |
| Yu, CY | 1 |
| Lu, WF | 1 |
| Zhou, CN | 1 |
| Wu, M | 1 |
| Lin, DX | 1 |
| MATSUURA, K | 1 |
| IMADA, R | 1 |
| FUJII, K | 1 |
| RYAN, WL | 1 |
| LORINCZ, AB | 1 |
| FAGE, P | 1 |
| Ciszkowska-Łysoń, B | 1 |
| Królicki, L | 1 |
| Teska, A | 1 |
| Janowicz-Zebrowska, A | 1 |
| Krzakowski, M | 1 |
| Tacikowska, M | 1 |
| Ito, H | 1 |
| Hamajima, N | 1 |
| Mitsudomi, T | 1 |
| Sugiura, T | 1 |
| Saito, T | 1 |
| Yasue, T | 1 |
| Lee, KM | 1 |
| Kang, D | 1 |
| Yoo, KY | 1 |
| Sato, S | 1 |
| Ueda, R | 1 |
| Tajima, K | 1 |
| Esplin, ED | 1 |
| Ramos, P | 1 |
| Martinez, B | 1 |
| Tomlinson, GE | 1 |
| Mumby, MC | 1 |
| Evans, GA | 1 |
| Creech, RH | 2 |
| Tritchler, D | 2 |
| Ettinger, DS | 2 |
| Ferraro, JA | 1 |
| Ruckdeschel, JC | 1 |
| Vogl, SE | 1 |
| Woll, J | 1 |
| Monks, A | 1 |
| Anderson, LW | 1 |
| Strong, J | 1 |
| Cysyk, RL | 2 |
| Earhart, R | 1 |
| Wanner, MJ | 1 |
| Hageman, JJ | 1 |
| Koomen, GJ | 1 |
| Pandit, UK | 1 |
| Kensler, TW | 2 |
| Mutter, G | 1 |
| Hankerson, JG | 1 |
| Reck, LJ | 2 |
| Harley, C | 1 |
| Han, N | 1 |
| Ardalan, B | 2 |
| Johnson, RK | 4 |
| Jayaram, HN | 1 |
| Cooney, DA | 3 |
| Cleaveland, ES | 1 |
| Zaharevitz, DW | 1 |
| Kelley, JA | 1 |
| Paull, K | 1 |
| Ford, H | 1 |
| Paranavitana, CM | 1 |
| Fukuoka, K | 1 |
| Nishio, K | 1 |
| Fukumoto, H | 1 |
| Arioka, H | 1 |
| Kurokawa, H | 1 |
| Ishida, T | 1 |
| Iwamoto, Y | 1 |
| Tomonari, A | 1 |
| Suzuki, T | 1 |
| Usuda, J | 1 |
| Narita, N | 1 |
| Saijo, N | 1 |
| Piao, CQ | 2 |
| Hei, TK | 2 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Mizumura, Y | 1 |
| Matsumura, Y | 1 |
| Hamaguchi, T | 1 |
| Nishiyama, N | 1 |
| Kataoka, K | 1 |
| Kawaguchi, T | 1 |
| Hrushesky, WJ | 1 |
| Moriyasu, F | 1 |
| Kakizoe, T | 1 |
| Wu, LJ | 1 |
| Willey, JC | 1 |
| Hall, EJ | 1 |
| Moyer, JD | 1 |
| Handschumacher, RE | 1 |
| Swyryd, EA | 1 |
| Stark, GR | 2 |
| Inouye, T | 1 |
| Goldin, A | 1 |
| Isoai, A | 1 |
| Ueno, Y | 1 |
| Giga-Hama, Y | 1 |
| Goto, H | 1 |
| Kumagai, H | 1 |
| Sridhar, KS | 1 |
| Benedetto, P | 1 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Daussin, F | 1 |
| Boschetti, E | 1 |
| Delmotte, F | 1 |
| Monsigny, M | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genotyping K-RAS and EGFR in Greek Non-small-cell Lung Cancer Patients: Incidence, Significance and Treatment Implications[NCT03951233] | 424 participants (Actual) | Observational | 2000-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aspartic acid and Lung Neoplasms
| Article | Year |
|---|---|
Polymorphism of ERCC2 Asp312Asn with lung cancer risk: evidence from 20,101 subjects.
Topics: Asparagine; Aspartic Acid; Case-Control Studies; Humans; Lung Neoplasms; Polymorphism, Genetic; Xero | 2014 |
4 trials available for aspartic acid and Lung Neoplasms
| Article | Year |
|---|---|
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcin | 1984 |
Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Humans | 1984 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
41 other studies available for aspartic acid and Lung Neoplasms
| Article | Year |
|---|---|
[Mechanism of Cordyceps militaris against non-small cell lung cancer: based on serum metabolomics].
Topics: Alanine; Animals; Arginine; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cordyceps; Glu | 2022 |
Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
Topics: Animals; Asparaginase; Asparagine; Aspartate-Ammonia Ligase; Aspartic Acid; Carcinogenesis; Carcinom | 2022 |
Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Topics: Animals; Aspartic Acid; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Co | 2021 |
Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aspartic Acid; Breast Neoplasms; Cancer-Associated Fi | 2019 |
[In silico study of a functional mutation associated with non-small cell lung cancer: G12D mutation of exon 2 in KRAS gene].
Topics: Algeria; Amino Acid Substitution; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Computational Biolo | 2019 |
[Preparation, characterization and Calu-3 cellular uptake of three kinds of poly(b-benzyl-L-amino)block-poly(ethylene glycol) nanoparticles].
Topics: Adenocarcinoma; Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid; | 2013 |
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Asian People; Aspartic Acid; Female; Genetic Predispo | 2014 |
Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Aspartic Acid; Brain Neoplasms; Cell Line, Tumo | 2015 |
Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery.
Topics: Antineoplastic Agents; Apoferritins; Aspartic Acid; Cell Line, Tumor; Drug Carriers; Drug Delivery S | 2015 |
Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.
Topics: Acetyltransferases; Adult; Aged; Aspartic Acid; Biomarkers, Tumor; Blood-Brain Barrier; Carcinoma, N | 2016 |
Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion.
Topics: Action Potentials; Adenosine Triphosphate; Aldehyde Dehydrogenase; Animals; Aspartic Acid; Carcinoma | 2016 |
PHF20 Readers Link Methylation of Histone H3K4 and p53 with H4K16 Acetylation.
Topics: Acetylation; Amino Acid Sequence; Antigens, Neoplasm; Aspartic Acid; Biomarkers, Tumor; Cell Line, T | 2016 |
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Topics: A549 Cells; Adenosine Triphosphate; Animals; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cell Cyc | 2016 |
ATB
Topics: Amino Acid Transport Systems; Amino Acid Transport Systems, Neutral; Antineoplastic Agents; Aspartic | 2017 |
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Cyclin-Depen | 2010 |
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Topics: Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, Phase II as Topic; | 2012 |
[An antimetastatic study of Arg-Asp (RD) on salivary adenoid cystic carcinoma in vivo].
Topics: Animals; Antineoplastic Agents; Arginine; Aspartic Acid; Carcinoma, Adenoid Cystic; Dose-Response Re | 2002 |
[Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing].
Topics: Adenocarcinoma; Asparagine; Aspartic Acid; Carcinoma, Squamous Cell; China; DNA; DNA Helicases; DNA | 2003 |
[L-ASPARTIC ACID K,MG SALTS FOR RADIATION SICKNESS].
Topics: Animals; Aspartic Acid; Female; Japan; Lung Neoplasms; Magnesium; Mice; Neoplasms; Potassium; Radiat | 1963 |
FREE AMINO ACIDS OF HUMAN BREAST CANCER.
Topics: Amino Acids; Asparagine; Aspartic Acid; Breast Neoplasms; Chromatography; Citrulline; Glutamates; Gl | 1964 |
[CLINICAL TRIALS OF A DRUG COMBINATION GROUPING THE ANTITOXIC FRACTIONS OF THE LIVER WITH ASPARTATES AND EXTRACTS OF THE LIVER WITH YEASTS].
Topics: Arteritis; Aspartic Acid; Drug Combinations; Geriatrics; Hernia, Diaphragmatic; Hernia, Hiatal; Huma | 1964 |
[Brain metabolic disorders after chemotherapy in the study by magnetic resonance spectroscopy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain; Brain Diseases, M | 2003 |
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk.
Topics: Adult; Aged; Alleles; Arginine; Aspartic Acid; Codon; DNA Repair; DNA-(Apurinic or Apyrimidinic Site | 2004 |
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
Topics: Amino Acid Substitution; Aspartic Acid; Base Sequence; Breast Neoplasms; DNA Primers; Female; Geneti | 2006 |
Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbon Diox | 1983 |
Potential carcinostatics. 4. Synthesis and biological properties of erythro- and threo-beta-fluoroaspartic acid and erythro-beta-fluoroasparagine.
Topics: Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Female; Leukemia L5178; Lung Neoplasms; M | 1980 |
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Topics: Amides; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma; Cell Line; Dose-Response | 1981 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1981 |
Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Topics: Antineoplastic Agents; Aspartic Acid; Biphenyl Compounds; Breast Neoplasms; Carbolines; Carcinoma, N | 1996 |
Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization.
Topics: Alanine; Amino Acid Substitution; Animals; Aspartic Acid; Breast Neoplasms; Codon; Colonic Neoplasms | 1998 |
Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aspartic Acid; Camptothecin; Carcinoma, Non-Small-Cell | 2000 |
Gene amplification and microsatellite instability induced in tumorigenic human bronchial epithelial cells by alpha particles and heavy ions.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic | 2001 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Cell Survival; Cisplatin; Colonic Neoplasms; Drug Carriers | 2001 |
Genomic instability and tumorigenic induction in immortalized human bronchial epithelial cells by heavy ions.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Aspartic Acid; Bronchi; Cell Fusion; Cell Line, Tra | 1998 |
Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Female; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred | 1979 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Body Weight; Carbamates; Lung Neoplasms; Male; Mice; | 1977 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |
A novel Arg-Gly-Asp containing peptide specific for platelet aggregation and its effect on tumor metastasis: a possible mechanism of RGD peptide-mediated inhibition of tumor metastasis.
Topics: Animals; Anticarcinogenic Agents; Arginine; Aspartic Acid; Carcinoma, Squamous Cell; Cell Adhesion; | 1992 |
p-Benzylthiocarbamoyl-aspartyl-daunorubicin-substituted polytrisacryl. A new drug acid-labile arm-carrier conjugate.
Topics: Acrylates; Aspartic Acid; Binding Sites; Carcinoma; Cell Survival; Daunorubicin; Hydrogen-Ion Concen | 1988 |